XML 112 R61.htm IDEA: XBRL DOCUMENT
v3.23.4

Fair Value Measurements - Narrative (Details) - USD ($) |  |  |  |  |  |  | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2023 | Sep. 29, 2023 | Jul. 07, 2023 | Jun. 30, 2023 | Jun. 26, 2023 | Jun. 22, 2023 | Sep. 30, 2023 | Jun. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | May 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Financial liabilities outstanding measured at fair value |  |  |  |  |  |  |  |  |  |  |  | $ 0 |  |  |
Stock-based compensation |  |  |  |  |  |  |  |  |  | $ 8,405,000 | $ 5,684,000 | 7,111,000 | $ 8,038,000 | $ 6,256,000 |
Fair value assets transferred from level 1 to level 2 |  |  |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 |  |
Forward contract liability |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Financial liabilities outstanding measured at fair value |  |  |  | $ 164,300,000 |  | $ 106,200,000 | $ 0 | $ 164,300,000 |  | 0 |  |  |  |  |
Liabilities, fair value |  |  |  |  |  | $ 106,200,000 |  |  |  |  |  |  |  |  |
Change in fair value of forward contract liability |  |  |  |  |  |  | 25,360,000 |  | $ 0 | 83,530,000 | 0 |  |  |  |
Change in fair value of liability |  |  |  | $ (58,100,000) |  |  | (25,400,000) |  |  |  |  |  |  |  |
Spyre Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Asset acquisition, stockholder payment period |  |  |  |  |  | 3 years |  |  |  |  |  |  |  |  |
Asset acquisition, cash payment, threshold period |  |  |  |  |  | 1 year |  |  |  |  |  |  |  |  |
CVR liability |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Change in fair value of liability |  |  |  |  |  |  | 1,300,000 | 1,300,000 |  |  |  |  |  |  |
Parapyre Option Obligation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of annual equity grant of options |  |  |  |  |  | 1.00% |  |  |  |  |  |  |  |  | 1.00%
Share-based payment award, term |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of contingent consideration assumed |  |  |  |  |  | $ 100,000 |  |  |  |  |  |  |  |  |
Stock-based compensation |  |  |  |  |  |  | 2,700,000 |  | $ 0 | $ 2,900,000 | $ 0 |  |  |  |
Parapyre Option Obligation | Forecast |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pro-rated estimated fair value of options | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Series A Non Voting Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of Series A non-voting convertible preferred stock |  |  | $ 189,700,000 |  | $ 197,300,000 |  | $ 189,741,000 | $ 197,323,000 |  |  |  |  |  |  |
Series A Non Voting Convertible Preferred Stock | Asset Acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares transferred as equity interest in asset acquisition |  |  |  |  |  | 364,887 |  |  |  |  |  |  |  |  |
Series A Non Voting Convertible Preferred Stock | Spyre Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares transferred as equity interest in asset acquisition |  |  |  |  |  | 364,887 |  |  |  |  |  |  |  |  |

X
- Definition Asset Acquisition, Cash Payment, Threshold Period + References No definition available. + Details
Name: | agle_AssetAcquisitionCashPaymentThresholdPeriod
Namespace Prefix: | agle_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset acquisition consideration transferred equity interest issued and issuable, shares. + References No definition available. + Details
Name: | agle_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
Namespace Prefix: | agle_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Stockholder Payment Period + References No definition available. + Details
Name: | agle_AssetAcquisitionStockholderPaymentPeriod
Namespace Prefix: | agle_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value assets level1 To level2 transfers amount1. + References No definition available. + Details
Name: | agle_FairValueAssetsLevel1ToLevel2TransfersAmount1
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of annual equity grant of options to purchase outstanding shares of common stock. + References No definition available. + Details
Name: | agle_PercentageOfAnnualEquityGrantOfOptionsToPurchaseOutstandingSharesOfCommonStock
Namespace Prefix: | agle_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Granted In Period, Fair Value + References No definition available. + Details
Name: | agle_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue
Namespace Prefix: | agle_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of contingent consideration recognized as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3 + Details
Name: | us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A + Details
Name: | us-gaap_GainLossOnDerivativeInstrumentsNetPretax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Fair value of financial and nonfinancial obligations. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_LiabilitiesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of noncash expense for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_ShareBasedCompensation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of new stock classified as temporary equity issued during the period. + References No definition available. + Details
Name: | us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=agle_SpyreTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=agle_ContingentValueRightLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=agle_ParapyreOptionObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=agle_SeriesANonVotingConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=agle_AssetAcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |